X
Menu

Science Advisory Board

To position itself at the forefront of the biomanufacturing landscape, Vitrian formed a Science Advisory Board comprised of subject matter experts across advanced therapeutics development and contract manufacturing, clinical operations, CQV, private equity, and venture capital. The Science Advisory Board complements Vitrian’s in-house expertise with a breadth of perspectives and decades of experience.

  • Jim Graham, CFA, MBA,
    Research Bridge Partners

    • Managing Director of Investments for TX- based life science VC firm focused on bringing coastal funders to support university- adjacent early-stage biotech companies outside of the coastal gateway clusters
    • Former bio company executive with experience in standing up and exiting commercial manufacturing operations
    • Extensive experience/relationships in TX life science community

  • Jeff Gilmore, PE, PMP
    cGMPNow

    • President and Managing Partner of market- leading project management, process development and technical support consultant for cGMP biomanufacturing
    • Previously co-founded Vista Engineering Group,provider of owner’s rep and engineering services for bio companies
    • Over 30 years’ experience standing up pilot scale to full commercialization manufacturing facilities
    • Extensive experience/relationships in Southern CA and CO life science communities

  • Brian Radecki
    Rapa Therapeutics

    • Founder and CEO of MD-based clinical-stage cell therapy company focused on cancer, neurodegenerative and autoimmune diseases spun out of National Cancer Institute in 2017.
    • Former CFO, CoStar Group
    • Active angel investor and board member of ACV Auctions, Wheels Up Partners Holdings, and Rosecliff Acquisitions Corp.

  • Deborah Wild

    • Advisory Board Member of GeneVentiv Therapeutics
    • Over 30 years’ biopharma executive experience with focus on advanced therapeutics at Cellipont Bioservices, Paragon/Catalent, and Genentech.
    • President and CEO of Southern CA and TX-based cell and gene therapy CDMO, former Chief Quality and Regulatory Affairs Officer and Chief of Staff at Paragon Bioservices
    • US Army Veteran and board member of several non-profits focused on veterans support
    • Extensive experience/relationships in Southern CA and MD life science communities

  • Tyler Brous
    Lennox Capital Partners, TX-based biotech and real estate investment firm

    • Managing Director at Lennox Capital Partners
    • Serves on ColdQuanta’s board of directors
    • Previously worked at Arog Pharmaceuticals, an oncology focused pharmaceutical company, in various roles including CFO

  • Isaac Ro
    Catalio Capital Management / Haystack Oncology

    • Over 20 years of experience in the life sciences sector with a particular focus on genomics, oncology and bioproduction
    • Partner at Catalio Capital Management, LP
    • Executive Chairman of Haystack Oncology. Previously, he served as CFO of Sema4 (went public in 2021) and CFO of Thrive Earlier Detection (acquired by Exact Sciences for $2.1 billion)
    • Before that, 16 years on Wall Street as an award-winning equity research analyst at Goldman Sachs and SVB Securities

  • Scott Rizzo
    COO and Senior VP
    Societal CDMO

    • Over 30 years’ of leadership and operational experience primarily in oral solid dose (OSD) manufacturing.
    • Held positions at Roche Pharmaceuticals, Barrier Therapeutics, J. Knipper, Dupont, and PWC
    • Board Member of Georgia Bio and leads employee development and community relations endeavors with Greater Hall Chamber of Commerce

  • Yun Jeong Song, MD
    Matica Biotechnology

    • President of Matica Holdings
    • Over 20 years of research, patient care, and immuno-oncology therapy development background
    • Former CEO/CMO of ImmuneOncia and Clinical Director at Sanofi
    • Extensive experience/relationships in Korea and Korean-American life science communities
STAY IN TOUCH

CONTACT US

For inquiries or more information, contact us at 240.396.1414
or fill out the form below.

This field is for validation purposes and should be left unchanged.
arrow